Vision Point Advisory Group, LLC Exelixis, Inc. Transaction History
Vision Point Advisory Group, LLC
- $473 Million
- Q3 2025
A detailed history of Vision Point Advisory Group, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Vision Point Advisory Group, LLC holds 5,738 shares of EXEL stock, worth $207,313. This represents 0.05% of its overall portfolio holdings.
Number of Shares
5,738Holding current value
$207,313% of portfolio
0.05%Shares
1 transactions
Others Institutions Holding EXEL
# of Institutions
686Shares Held
259MCall Options Held
1.41MPut Options Held
1.55M-
Black Rock Inc. New York, NY33.5MShares$1.21 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA27.5MShares$992 Million0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA16MShares$579 Million3.18% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.8MShares$572 Million0.99% of portfolio
-
State Street Corp Boston, MA11.4MShares$411 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.6B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...